Drug Index


Mechanism :

Sumatriptan is an agonist for 5-hydroxytryptamine1 receptor subtype having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity for 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1; dopamine2; muscarinic, or benzodiazepine receptors.

Indication :

  • Acute attack of Migraine

Contraindications :

Contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes, all forms of myocardial infarction, and silent myocardial ischemia, coronary vasospasm and uncontrolled hypertension.

Dosing :

Oral: As single dose.
6-10 years: 25 mg
10-12 years: 50 mg
12-18 years: 50-100 mg

Adverse Effect :

Rarely serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan including coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation, nausea, vomiting, seizures, transient tingling sensation, heaviness, flushing, dizziness, weakness and hypersensitivity reactions.

Interaction :

MAO-A Inhibitors: Reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of sumatriptan tablets in patients receiving MAO-A inhibitors is contraindicated.
Selective Serotonin Reuptake Inhibitors Fluoxetine, Fluvoxamine, Paroxetine, Sertraline: Rarely cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function, use with caution
<10Dose as in normal renal function, use with caution

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnknown dialysability. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in normal renal function. Use with caution

Hepatic Dose :

Mild to Moderate hepatic Impairment:
Intranasal preparation: No dose adjustment recommended.
Oral preparation: Hepatic impairment increases bioavailability of the drug. Use is not recommended. However if required, the maximum dose that can be given is 50mg a dose in adults.
Subcutaneous preparation: No dose adjustment recommended.

Severe hepatic impairment: Do not use sumatriptan.
11/05/2023 20:59:20 Sumatriptan
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0